Author

Marcelo Horacio Losso

Observed names: Losso, M, M Losso, M. Losso, M.H. Losso, Marcelo H. Losso, Marcelo H Losso, Marcelo H. Losso, Marcelo Losso, Marcelo H. Losso

Institution: Hospital Ramos Mejía

Observed institutions: University of California, Los Angeles, Universidade de São Paulo, National University of Mar del Plata, Hospital Italiano de Buenos Aires, Rigshospitalet, Fred Hutch Cancer Center, Secretaria de Salud, San Francisco Department of Public Health, Hospital Ramos Mejía, Hospital San Juan de Dios, National Institute of Allergy and Infectious Diseases, Association Clinique et Thérapeutique Infantile du Val de Marne, Gilead Sciences (United States), GlaxoSmithKline (Brazil), Hospital San Borja Arriarán, Harbor–UCLA Medical Center, Fundacion Ibis Para la Investigacion de HIV/SIDA, University of Chile, Louisiana State University Health Sciences Center New Orleans

ORCID: 0000-0002-4273-4833

Observed ORCID: 0000-0002-4273-4833

OpenAlex ID: A5079967288

A Randomized Trial of Convalescent Plasma in Covid-19 Severe Pneumonia

2020 · Ventura A. Simonovich, Leandro D. Burgos Pratx, et al. · New England Journal of Medicine · 907

Cabotegravir for HIV Prevention in Cisgender Men and Transgender Women

2021 · Raphael J. Landovitz, Deborah Donnell, et al. · New England Journal of Medicine · 900

PDF

Remdesivir and three other drugs for hospitalised patients with COVID-19: final results of the WHO Solidarity randomised trial and updated meta-analyses

2022 · Hongchao Pan, Richard Peto, et al. · The Lancet · 394

PDF

Twice-Yearly Lenacapavir for HIV Prevention in Men and Gender-Diverse Persons

2024 · Colleen F. Kelley, Maribel Acevedo-Quiñones, et al. · New England Journal of Medicine · 297

Dolutegravir versus ritonavir-boosted lopinavir both with dual nucleoside reverse transcriptase inhibitor therapy in adults with HIV-1 infection in whom first-line therapy has failed (DAWNING): an open-label, non-inferiority, phase 3b trial

2019 · Michael Aboud, Richard Kaplan, et al. · The Lancet Infectious Diseases · 192

Sequence Analysis of In Vivo Defective Interfering-Like RNA of Influenza A H1N1 Pandemic Virus

2013 · Kazima Saira, Xudong Lin, et al. · Journal of Virology · 170

Anti-influenza hyperimmune intravenous immunoglobulin for adults with influenza A or B infection (FLU-IVIG): a double-blind, randomised, placebo-controlled trial

2019 · Richard T Davey, Eduardo Fernández-Cruz, et al. · The Lancet Respiratory Medicine · 127

PDF

Efficacy and safety of efavirenz 400 mg daily versus 600 mg daily: 96-week data from the randomised, double-blind, placebo-controlled, non-inferiority ENCORE1 study

2015 · Dianne Carey, Rebekah Puls, et al. · The Lancet Infectious Diseases · 113

Oseltamivir, amantadine, and ribavirin combination antiviral therapy versus oseltamivir monotherapy for the treatment of influenza: a multicentre, double-blind, randomised phase 2 trial

2017 · John H Beigel, Yajing Bao, et al. · The Lancet Infectious Diseases · 98

Infectious Disease Morbidity Among Young HIV-1–Exposed But Uninfected Infants in Latin American and Caribbean Countries: The National Institute of Child Health and Human Development International Site Development Initiative Perinatal Study

2007 · Marisa M. Mussi-Pinhata, Laura Freimanis, et al. · PEDIATRICS · 95

Factors Associated with D-Dimer Levels in HIV-Infected Individuals

2014 · Álvaro H. Borges, Jemma L. O’Connor, et al. · PLoS ONE · 86

PDF

Pharmacokinetic Parameters of Nevirapine and Efavirenz in Relation to Antiretroviral Efficacy

2006 · F. Van Leth, B.S. Kappelhoff, et al. · AIDS Research and Human Retroviruses · 80

Baseline HIV-1 resistance, virological outcomes, and emergent resistance in the SECOND-LINE trial: an exploratory analysis

2015 · Mark A Boyd, Cecilia L Moore, et al. · The Lancet HIV · 79

Pharmacokinetic and Pharmacodynamic Comparison of Once‐Daily Efavirenz (400 mg vs. 600 mg) in Treatment‐Naïve HIV‐Infected Patients: Results of the ENCORE1 Study

2015 · L Dickinson, J Amin, et al. · Clinical Pharmacology & Therapeutics · 75

PDF

Contribution of Genetic Background, Traditional Risk Factors, and HIV-Related Factors to Coronary Artery Disease Events in HIV-Positive Persons

2013 · Margalida Rotger, Tracy R. Glass, et al. · Clinical Infectious Diseases · 74

PDF

When should antiretroviral therapy for HIV be started?

2007 · Andrew N Phillips, Brian G Gazzard, et al. · BMJ · 74

PDF

Abatacept, Cenicriviroc, or Infliximab for Treatment of Adults Hospitalized With COVID-19 Pneumonia

2023 · Jane A. O’Halloran, Emily R. Ko, et al. · JAMA · 70

PDF

Thymidine Analogue Mutation Profiles: Factors Associated with Acquiring Specific Profiles and their Impact on the Virological Response to Therapy

2005 · Alessandro Cozzi-Lepri, Lidia Ruiz, et al. · Antiviral Therapy · 69

PDF

A Randomized, Controlled, Phase II Trial Comparing Escalating Doses of Subcutaneous Interleukin‐2 plus Antiretrovirals versus Antiretrovirals Alone in Human Immunodeficiency Virus–Infected Patients with CD4+Cell Counts ⩾350/mm3

2000 · Marcelo H. Losso, Waldo H. Belloso, et al. · The Journal of Infectious Diseases · 66

Fatal and nonfatal AIDS and non-AIDS events in HIV-1-positive individuals with high CD4 cell counts according to viral load strata

2011 · Joanne Reekie, Jose M. Gatell, et al. · AIDS · 61

Comprehensive Pharmacokinetic, Pharmacodynamic and Pharmacogenetic Evaluation of Once-Daily Efavirenz 400 and 600 mg in Treatment-Naïve HIV-Infected Patients at 96 Weeks: Results of the ENCORE1 Study

2015 · Laura Dickinson, Janaki Amin, et al. · Clinical Pharmacokinetics · 52

PDF

Antiretroviral Adherence During Pregnancy and Postpartum in Latin America

2012 · Regis Kreitchmann, D. Robert Harris, et al. · AIDS Patient Care and STDs · 48

Randomized, Controlled Study of the Effects of a Short Course of Prednisone on the Incidence of Rash Associated With Nevirapine in Patients Infected With HIV-1

2003 · Julio S.G. Montaner, Pedro Cahn, et al. · JAIDS Journal of Acquired Immune Deficiency Syndromes · 47

Association Between Single-Nucleotide Polymorphisms in HLA Alleles and Human Immunodeficiency Virus Type 1 Viral Load in Demographically Diverse, Antiretroviral Therapy–Naive Participants From the Strategic Timing of AntiRetroviral Treatment Trial

2019 · Christina Ekenberg, Man-Hung Tang, et al. · The Journal of Infectious Diseases · 42

PDF

Hepatitis C Virus Coinfection Does Not Influence the CD4 Cell Recovery in HIV-1-Infected Patients With Maximum Virologic Suppression

2009 · Lars Peters, Amanda Mocroft, et al. · JAIDS Journal of Acquired Immune Deficiency Syndromes · 42

Works count: 131

Citation count: 5,347

H-index: 32

I10-index: 64